Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Relmada Therapeutics, Incorporated Quarter 4 2024 Financial Results Call. At this time, all participants are in a listen-only mode.
Relmada Therapeutics Inc. (RLMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Palo Alto Investors William Leland Edwards | 495,146 | $257,476 | -33% | 0.03% |
| 2. | Tang Capital Management Kevin C. Tang | 200,825 | $104,429 | +296% | 0% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 198,900 | $103,428 | -18% | 0% |
| 4. | Renaissance Technologies Jim Simons | 164,513 | $85,547 | +536% | 0% |
| 5. | 129,800 | $67,496 | +94% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.99 | 51,407 | Officer, Director | 384,024 | 2024-09-11 | Filing | |
| $2.75 | 33,014 | Officer, Director | 332,617 | 2024-09-10 | Filing | |
| $2.71 | 55,579 | Officer, Director | 299,603 | 2024-09-09 | Filing | |
| $2.56 | 13,000 | Director | 13,000 | 2024-09-09 | Filing | |
| $2.95 | 24,120 | Officer | 88,335 | 2024-09-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.32 | 4,068 | Officer, Director | 88,774 | 2022-07-01 | Filing | |
| $18.45 | 8,848 | Officer, Director | 92,842 | 2022-07-01 | Filing | |
| $18.48 | 839 | Officer, Director | 101,690 | 2022-07-01 | Filing | |
| $19.01 | 10,698 | Officer, Director | 88,774 | 2022-06-30 | Filing | |
| $19.37 | 5,314 | Officer, Director | 99,472 | 2022-06-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 163,336 | $44,101 | 0% | |
| 2. | 48,962 | $13,220 | 0.01% | |
| 3. | 25,000 | $6,750 | 0% |
News See All
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2024 Earnings Call Transcript
Operator: Hello and welcome to the Relmada Therapeutics Third Quarter 2024 Earnings Conference Call.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. Welcome to the Relmada Therapeutics Inc.'s Second Quarter 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the Relmada Therapeutics Inc. First Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.84, expectations were $-0.88.
11 Best Psychedelic Stocks to Buy in 2024
Unlike substances like marijuana or cocaine, psychedelics are potent and serve as a form of gateway to an 'alternate reality' for those who use them.
5 Most Promising Psychedelic Stocks According to Hedge Funds
In this piece, we will take a look at the five most promising psychedelic stocks according to hedge funds.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Quarter 2023 Earnings Conference Call. At this time, all lines are in listen-only mode.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2023 Earnings Call Transcript
Operator: Greetings, and welcome to Relmada Therapeutics Inc. Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2023 Earnings Call Transcript
Operator: Good afternoon. Thank you for attending today's Relmada Therapeutics Inc. First Quarter 2023 Earnings Call. My name is Forum , and I will be your moderator for today's call.